Alphatec Hlds (ATEC) Stock Forecast & Price Target

Alphatec Holdings is viewed positively because its core spine surgery franchise is still growing at a strong pace, with 1Q26 surgery revenue of $178M up 17% year over year, case volume up 21%, and net new surgeon users up 23%. Even with EOS revenue weakness from installation timing and sales-marketing execution gaps, the underlying fundamentals remain intact, management has already taken corrective action, and the platform is expected to improve more meaningfully in 2H26. Strong margin performance also supports the outlook, as gross margin reached 71.0%, adjusted EBITDA was $20.7M versus a $14M target, and the company remains on track for its full-year $20M FCF target.

Alphatec Holdings is facing a weakened near-term outlook because EOS imaging produced only $14M in quarterly revenue, down 18% year over year, and management blamed poor sales execution and missed hardware deals for the shortfall. The company also cut 2026 revenue guidance to $882M from $890M, while 1Q26 revenue of $192M missed the $197M consensus and the net loss of $0.22 per share was far wider than the expected $0.02 loss, signaling execution and margin pressure. Even though adjusted EBITDA guidance of $134M and FCF of $20M were reiterated, the heavier reliance on a revamp of EOS sales, plus pricing, competition, and regulatory risks, supports a cautious stance.